-
公开(公告)号：US20180311251A1
公开(公告)日：2018-11-01
申请号：US15580908
申请日：2016-06-10
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61P35/00 , A61K45/06 , G01N33/574
CPC分类号： A61K31/4412 , A61K31/444 , A61K31/5377 , A61K45/06
摘要： The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20240277721A1
公开(公告)日：2024-08-22
申请号：US18431262
申请日：2024-02-02
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61K31/167 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/7068 , A61K33/243 , A61K45/06
CPC分类号： A61K31/5377 , A61K31/167 , A61K31/337 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/7068 , A61K33/243 , A61K45/06
摘要： The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. In some embodiments, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat lung cancer, e.g., non-small cell lung cancer.
-
公开(公告)号：US20240182426A1
公开(公告)日：2024-06-06
申请号：US18482475
申请日：2023-10-06
申请人： Epizyme, Inc.
IPC分类号： C07D231/12 , A61K31/415 , A61K31/4155 , C07D401/04 , C07D403/04 , C07D403/08 , C07D405/04 , C07D405/08 , C07D405/12 , C07D493/10
CPC分类号： C07D231/12 , A61K31/415 , A61K31/4155 , C07D401/04 , C07D403/04 , C07D403/08 , C07D405/04 , C07D405/08 , C07D405/12 , C07D493/10
摘要： Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.
-
公开(公告)号：US20240180919A1
公开(公告)日：2024-06-06
申请号：US18496074
申请日：2023-10-27
申请人： Epizyme, Inc.
发明人： Scott RIBICH , Michael THOMENIUS
IPC分类号： A61K31/5377 , A61K9/00 , A61P35/00
CPC分类号： A61K31/5377 , A61K9/0053 , A61P35/00 , A61K45/06
摘要： The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20240173320A1
公开(公告)日：2024-05-30
申请号：US18466908
申请日：2023-09-14
申请人： Epizyme, Inc.
发明人： Kat COSMOPOULOS , Elayne Penebre
IPC分类号： A61K31/506 , A61K31/416 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5025 , A61K31/52 , A61K31/5377 , A61K31/541 , A61K31/5513
CPC分类号： A61K31/506 , A61K31/416 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5025 , A61K31/52 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K45/06
摘要： The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.
-
公开(公告)号：US20240041895A1
公开(公告)日：2024-02-08
申请号：US18188721
申请日：2023-03-23
申请人： Epizyme, Inc.
IPC分类号： A61K31/5377 , A61P35/00 , A61K31/282 , A61K31/4184 , A61K31/436 , A61K31/4406 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/519 , A61K31/55 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K38/15 , A61N5/10
CPC分类号： A61K31/5377 , A61P35/00 , A61K31/282 , A61K31/4184 , A61K31/436 , A61K31/4406 , A61K31/4745 , A61K31/475 , A61K31/506 , A61K31/519 , A61K31/55 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K38/15 , A61N5/10
摘要： The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.
-
公开(公告)号：US20230201213A1
公开(公告)日：2023-06-29
申请号：US17927419
申请日：2021-05-27
申请人： Epizyme, Inc.
发明人： Carly CAMPBELL , Kat COSMOPOULOS , Alice MCDONALD , Melinda MERCHANT , Neil MICHAUD , Attila SZANTO
IPC分类号： A61K31/5377 , A61P35/00 , C12Q1/6886
CPC分类号： A61K31/5377 , A61P35/00 , C12Q1/6886 , C12Q2600/158 , C12Q1/6869
摘要： The present disclosure provides methods for the treatment of a cancer characterized by at least one tumor comprising intratumoral B cells and/or stromal B cells, in a subject, comprising administering to the subject an EZH2 inhibitor. The present disclosure also provides methods of identifying a subject having cancer for treatment with an EZH2 inhibitor of determining the response of a subject to an EZH2-inhibitor therapy, the methods comprising determining the level of intratumoral B cells and/or stromal B cells. The present disclosure also provides a method of decreasing the number and/or density of intratumoral B cells and/or stromal B cells in a tumor in a subject, comprising administering to the subject an EZH2 inhibitor.
-
公开(公告)号：US11685732B2
公开(公告)日：2023-06-27
申请号：US16766890
申请日：2018-11-29
申请人： Epizyme, Inc.
IPC分类号： C07D403/12 , C07D309/06 , C07D309/08 , C07D231/12 , C07D231/56 , C07D471/10 , C07D263/28 , C07D263/50 , C07D205/04 , C07D265/30 , C07D207/08 , C07D275/03 , C07C311/19 , C07C311/32 , C07C311/49 , C07C255/00 , C07C307/02 , C07C317/50 , A61K31/40 , A61K31/18 , A61K31/165 , A61P35/00 , C07D405/12 , C07D211/24 , C07D213/54 , C07D223/04 , C07D233/64 , C07D241/04 , C07D257/04 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/12
CPC分类号： C07D405/12 , C07C311/49 , C07D205/04 , C07D207/08 , C07D211/24 , C07D213/54 , C07D223/04 , C07D231/12 , C07D233/64 , C07D241/04 , C07D257/04 , C07D265/30 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/12
摘要： The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
-
公开(公告)号：US11672800B2
公开(公告)日：2023-06-13
申请号：US16606833
申请日：2018-04-20
申请人： Epizyme, Inc.
发明人： John Emmerson Campbell , Kenneth William Duncan , Maria Alejandra Raimondi , Christine Klaus , Elayne Penebre
IPC分类号： A61K31/505 , A61K31/506 , A61P35/00 , A61K31/203 , A61K31/4375 , A61K31/44 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/706
CPC分类号： A61K31/506 , A61K31/203 , A61K31/4375 , A61K31/44 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/706 , A61P35/00
摘要： The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
-
公开(公告)号：US11642349B2
公开(公告)日：2023-05-09
申请号：US17128634
申请日：2020-12-21
申请人： Epizyme, Inc.
发明人： Heike Keilhack , Sarah K. Knutson
IPC分类号： A61K31/5377 , A61K31/4412 , A61K31/4545 , A61P35/00 , A61K9/00
CPC分类号： A61K31/5377 , A61K9/0053 , A61K31/4412 , A61K31/4545 , A61P35/00
摘要： The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
-
-
-
-
-
-
-
-
-
搜索结果
325 条记录 (耗时 0.026 秒)
